Streetbeat News

Insider Trading

NVDA

Nvidia insiders have sold over $700 million in shares this year amid a 164% stock price surge driven by high demand for AI accelerator chips. Despite significant insider selling, the demand for Nvidia's products remains strong. However, analysts caution about potential stock pullbacks due to overbought conditions.

Portfolio Pulse from Benzinga Neuro

June 18, 2024 | 12:52 pm

CRWD

NVDA

PINS

WDAY

Insiders from Nvidia, CrowdStrike, Workday, and Pinterest have recently sold shares. Insider sales can indicate concerns about company prospects or overvaluation. Notable sales include CrowdStrike's Chief Security Officer, Workday's 10% owner, Nvidia's President and CEO, and Pinterest's Chief Accounting Officer.

Portfolio Pulse from Avi Kapoor

June 18, 2024 | 12:40 pm

BEEP

FPAY

HYLN

STXS

The article highlights recent insider transactions in four penny stocks: Stereotaxis, Mobile Infrastructure, Hyliion Holdings, and FlexShopper. Insider buying can indicate confidence in the company's prospects.

Portfolio Pulse from Avi Kapoor

June 18, 2024 | 12:10 pm

ARKK

CLF

HUMA

INTC

PARA

SOLV

Senator Tommy Tuberville disclosed multiple large trades, including sales of Cleveland-Cliffs, Intel, Humacyte, and Paramount Global stocks, and purchases of call and put options on the Ark Innovation ETF. He also made new buys in Intel and Solventum Corporation. Tuberville's trading activity has drawn scrutiny due to his committee assignments.

Portfolio Pulse from Chris Katje

June 17, 2024 | 10:45 pm

LLY

Eli Lilly and Company (LLY) has reported in a Form 4 filing that Lilly Endowment Inc. purchased 15,022 shares at an average price of $882.47 per share.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 8:02 pm

CRBP

Dr. Yong Ben, a board member of Corbus Pharmaceuticals (NASDAQ: CRBP), has adopted a Rule 10b5-1 trading plan to sell up to 10,607 shares of the company's stock. This plan, effective from September 12, 2024, to September 11, 2025, aims to avoid insider trading accusations. Corbus focuses on developing therapies for inflammatory and fibrotic diseases, with its lead product candidate, lenabasum, currently in clinical trials.

Portfolio Pulse from Javier Hasse

June 17, 2024 | 5:37 pm

AAN

ADSK

LXRX

MIRM

OUST

PRMW

XPOF

U.S. stocks were mostly lower on Monday, with the Dow Jones index falling around 0.2%. However, several stocks saw significant gains. Aaron's shares rose 32.2% after announcing an acquisition by IQVentures Holdings. Xponential Fitness, Lexicon Pharmaceuticals, Mirum Pharmaceuticals, United Homes Group, Ouster, Lufax Holding, Primo Water, Golar LNG, Autodesk, and Wayfair also recorded notable gains.

Portfolio Pulse from Avi Kapoor

June 17, 2024 | 1:59 pm

PEGY

On June 14, 2024, Pineapple Energy's Interim CEO Scott Maskin purchased 15,000 shares at an average price of $1.43 per share, according to an SEC Form 4 filing.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 1:19 pm

PEGY

Scott Maskin, Interim CEO of Pineapple Energy Inc. (PEGY), has purchased additional shares in the company, signaling confidence in its long-term viability in the renewable energy sector. The size or amount of the purchase was not disclosed.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 1:17 pm

NRDY

Nerdy Inc.'s CEO, Charles K. Cohn, has purchased 347,275 shares of the company's stock at an average price of $1.88 per share, according to a recent SEC Form 4 filing.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 1:15 pm